Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Palatin Technologies Inc (NYSE American:PTN)

0.82
Delayed Data
As of Oct 20
 +0.0022 / +0.27%
Today’s Change
0.29
Today|||52-Week Range
0.90
+62.34%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$146.8M

Company Description

Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. It specializes in molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. It offers product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder, which is a type of female sexual dysfunction, defined as low desire with associated distress. It also offers drug candidates and development programs for cardiovascular diseases and inflammatory diseases. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Contact Information

Palatin Technologies, Inc.
Cedar Brook Corporate Center
Cranbury New Jersey 08512
P:(609) 495-2200
Investor Relations:

Employees

Shareholders

Individual stakeholders7.82%
Other institutional7.57%
Mutual fund holders3.91%

Top Executives

Carl SpanaPresident, Chief Executive Officer & Director
Stephen T. WillsCOO, CFO, Secretary, Treasurer & Executive VP
Johna LucasChief Medical Officer